The growth in the forecast period can be attributed to growth in pediatric applications, expansion of indications, health benefits beyond growth, expansion of specialty pharmacy services and expansion of health insurance coverage. Major trends in the forecast period include development of microencapsulated growth, corticosteroid-sparing agents, pharmacogenomics for tailored dosing, advancements in continuous glucose monitoring (CGM) systems and microfluidic devices for hormone delivery.
The growth of the norditropin market is being driven by the increasing prevalence of chronic illnesses. Chronic illnesses are long-lasting conditions that require ongoing management and care. Factors such as poor lifestyle choices, urbanization, the obesity epidemic, chronic stress, improved diagnosis, environmental influences, genetic factors, and health disparities contribute to the rise in these conditions. Norditropin, a growth hormone therapy, helps manage chronic illnesses by promoting growth, enhancing metabolism, improving muscle strength, and supporting overall health in patients with conditions such as growth hormone deficiency, Turner syndrome, and Prader-Willi syndrome, ultimately improving their quality of life. For example, in December 2021, the International Diabetes Federation reported that around 537 million adults worldwide were living with diabetes, a number projected to rise to 643 million by 2030 and 783 million by 2045. This increasing burden of chronic illnesses is driving the norditropin market.
The growth of the norditropin market is also being fueled by the expansion of healthcare infrastructure. Healthcare infrastructure includes the physical and organizational resources required to deliver medical services. As healthcare infrastructure expands, it helps meet the growing demand for medical services, improves access to care, and supports the efficient delivery of high-quality healthcare. The expansion of healthcare facilities enables better access to advanced treatments, including growth hormone therapies such as norditropin, which are used to address growth-related disorders. For instance, in May 2023, the American Health Care Association reported that the number of hospitals in the U.S. increased from 5,129 in 2022 to 6,120 in 2023. This growth in healthcare infrastructure is contributing to the expansion of the norditropin market.
The increasing number of clinical trials is expected to further boost the norditropin market. Clinical trials are research studies designed to assess the safety, effectiveness, and potential side effects of medical treatments. The growing number of clinical trials reflects advancements in medical science and the need to address more complex healthcare challenges. These trials provide valuable data on the efficacy, safety, and dosing of norditropin, ensuring its regulatory approval and building confidence among healthcare providers and patients. For example, in November 2023, the Association of the British Pharmaceutical Industry reported a 4.3% increase in the number of industry-sponsored clinical trials initiated in the UK, from 394 trials in 2021 to 411 in 2022. This rise in clinical trials is driving the growth of the norditropin market.
The key company operating in the norditropin market is Novo Nordisk A/S
North America was the largest region in the norditropin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in norditropin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.The countries covered in the norditropin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Norditropin is a growth hormone therapy brand used to treat growth hormone deficiencies in both children and adults. In children, it helps stimulate growth when natural growth hormone is insufficient, and in adults, it addresses deficiencies that can impact metabolism, energy, and overall health. Administered through injection, Norditropin mimics the effects of the body’s natural growth hormone.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Norditropin is primarily indicated for growth hormone deficiency, Turner syndrome, and Prader-Willi syndrome. Growth hormone deficiency (GHD) is a rare but treatable condition that causes short stature in children and metabolic problems in adults. It is distributed through hospital pharmacies, retail pharmacies, and online platforms, serving various end users, including pediatric, adult, and geriatric populations.
The norditropin market consists of sales of products including norditropin flexpro, norditropin nordiflex, and norditropin simplexx. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Norditropin Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on norditropin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for norditropin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The norditropin market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Growth Hormone Deficiency; Turner Syndrome; Prader-Willi Syndrome2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Pediatric; Adult; Geriatric
Key Companies Profiled: Novo Nordisk A/S
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Novo Nordisk A/S